Breast cancer and osteolytic metastases: Can bisphosphonates help?

Nature Medicine

Volumn 3, Issue 2, 1997, Pages 151-152

  Siris, Ethel S ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

BONE METASTASIS; BREAST CANCER; HUMAN; OSTEOLYSIS; PREVENTION; PRIORITY JOURNAL; SHORT SURVEY;

BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS;

EID: 0031043555     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0297-151     Document Type: Short Survey

References (16)

1. Galasko, C.S.B. The anatomy and pathways of skeletal metastases, in Bone Metastasis. (eds. Weiss, L. & Gilbert, A. H.) 49-63 (G.K. Hall, Boston, 1981).
2. Hortobagyi, G.N. et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 333, 1785-1791 (1996).
3. van Breukelen, F.J.M. et al. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1, 803-805 (1979).
4. Siris, E.S., Hyman, G.A. & Canfield, R.E. Effects of dichloromethylene bisphosphonate in women with breast cancer metastatic to the skeleton. Am. J. Med. 74, 401-406 (1983).
5. Elomaa, I. et al. Long-term controlled trial of bisphosphonate in patients with osteolytic bone metastases. Lancet 1, 146-149 (1983).
6. Coleman, R.E. et al. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in patients with breast cancer. Br. J. Cancer 58, 621-625 (1988).
7. Fleisch, H. St Russell, R.G.G. Pyrophosphate and polyphosphate. in Encyclopedia (Int.) of Pharmacology and Therapeutics, Section 51. Pharmacology of the Endocrine System and Related Drugs. 61-100 (Pergamon, Oxford, New York, 1970).
8. Watts, N.B. et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 323, 73-79 (1990).
9. Liberman, U. et al. Effect of oral alendronate on bone mineral density and incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333, 1437-1443 (1995).
10. Kanis, J.A. Pathophysiology and Treatment of Paget's Disease of Bone. 159-216 (Dunitz, London, 1991).
11. Jacobs, T.P. et al. Neoplastic hypercalcemia: Physiologic response to intravenous etidronate disodium. Am. J. Med. 82 (Suppl. 2A), 42-50 (1987).
12. Nussbaum, S.R. et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30, 60, and 90 mg dosages. Am. J. Med. 95, 297-304 (1993).
13. Berenson, J.R. et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med. 334, 488-493 (1996).
14. Morton, A.R. et al. Sclerosis of lytic bone metastases after disodium aminohydroxy-propylidene bisphosphonate (APD) in patients with breast carcinoma. Br. Med. J. 297, 772-773 (1988).
15. Glover, D. et al. Intravenous pamidronate sodium treatment of bone metastases in patients with breast cancer: A dose seeking study. Cancer 74, 2949-2955 (1994).
16. Rodan, G.A. & Rodan, S.B. Osteoporosis: Etiology, Diagnosis and Management, (eds. Riggs, B.L. & Melton, L.J.) 12 (Raven, New York, 1988).